Stock Events

Stock Events

Immutep Limited 

$0.037900
74
-$0.01-24.2% Wednesday 17:11

Statistics

Day High
0.0379
Day Low
0.0325
52W High
0.33
52W Low
0.0325
Volume
30,000
Avg. Volume
187
Mkt Cap
5.59M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2SepExpected
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
-0.02
-0.01
-0.01
0
Expected EPS
-0.00251742381
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-39.53MNet Income

Analyst Ratings

1.00Average Price Target
The highest estimate is 1.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRRUF. It's not an investment recommendation.
NVIDIA
14
NVDA
Amazon
11
AMZN
Palantir Technologies
10
PLTR
Alphabet
9
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. competes with Immutep in the immuno-oncology space, particularly with their blockbuster drug Keytruda, which, like Immutep's lead candidate eftilagimod alpha, aims to enhance the immune system's ability to fight cancer.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb competes in the oncology and immuno-oncology sectors, offering drugs that directly compete with Immutep's pipeline by targeting similar pathways or mechanisms of action in cancer treatment.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech subsidiary, is involved in the development of immunotherapy treatments that compete with Immutep's products, especially in the field of cancer immunotherapy.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca PLC has a strong presence in the oncology sector, including immuno-oncology, with a portfolio that competes with Immutep's developments, particularly in combining therapies to enhance treatment efficacy.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. offers a range of oncology treatments, including immunotherapies that compete with Immutep's approach to cancer treatment, focusing on stimulating the immune system to attack cancer cells.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, Inc. competes with Immutep in the field of oncology and immuno-oncology, particularly with its focus on novel cancer therapies that could rival Immutep's product pipeline.
AMGEN
AMGN
Mkt Cap224.63B
Amgen Inc. has a diverse oncology portfolio, including immunotherapies that could compete with Immutep's efforts to modulate the immune system for cancer treatment.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments in oncology, including immuno-oncology, which could compete with Immutep's pipeline, especially in terms of novel mechanisms of action.
Novartis
NVS
Mkt Cap286.78B
Novartis AG has a strong focus on oncology and innovative cancer treatments, including immunotherapy, which positions it as a competitor to Immutep, especially in the development of new cancer treatment modalities.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its Janssen Pharmaceutical Companies, competes in the oncology space, including immunotherapy, with a broad range of products that could challenge Immutep's market position.

About

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Show more...
CEO
Marc Voigt
Employees
51
Country
Australia
ISIN
AU000000IMM6
WKN
000A2H81H

Listings

MU
DE
YP1A.MU
STU
DE
YP1B.STU
STU
DE
YP1A.STU
F
DE
YP1A.F

0 Comments

Share your thoughts

FAQ

What is Immutep Limited stock price today?▼
The current price of PRRUF is $0.04 USD — it has decreased by -24.2% in the past 24 hours. Watch Immutep Limited stock price performance more closely on the chart.
What is Immutep Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Immutep Limited stocks are traded under the ticker PRRUF.
Is Immutep Limited stock price growing?▼
PRRUF stock has fallen by -24.2% compared to the previous week, the month change is a -24.2% fall, over the last year Immutep Limited has showed a -80.05% decrease.
What is Immutep Limited market cap?▼
Today Immutep Limited has the market capitalization of 5.59M
When is the next Immutep Limited earnings date?▼
Immutep Limited is going to release the next earnings report on September 02, 2026.
What were Immutep Limited earnings last quarter?▼
PRRUF earnings for the last quarter are -0.02 USD per share, whereas the estimation was -0.02 USD resulting in a -7.02% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immutep Limited revenue for the last year?▼
Immutep Limited revenue for the last year amounts to 0 USD.
What is Immutep Limited net income for the last year?▼
PRRUF net income for the last year is -39.53M USD.
How many employees does Immutep Limited have?▼
As of August 20, 2026, the company has 51 employees.
In which sector is Immutep Limited located?▼
Immutep Limited operates in the Health & Wellness sector.
When did Immutep Limited complete a stock split?▼
The last stock split for Immutep Limited was on November 05, 2019 with a ratio of 1:10.
Where is Immutep Limited headquartered?▼
Immutep Limited is headquartered in Sydney, Australia.